X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

WHO Study Illustrates World Health Progress Despite Pandemic

Content Team by Content Team
19th May 2022
in Manufacturing, Middle East and South Asia, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

  • The study highlights COVAX’s delivery of 1.4 billion vaccination doses.
  • It also involves recommending the world’s first malaria vaccine.
  • The WHO’s REPLACE initiative aims to eliminate trans-fats by 2023.
  • About $500 million of PPE has been shipped globally.
  • Trans fatty acids are banned for 3.2 billion people in 58 nations.

Despite the COVID-19 outbreak, WHO’s 2020–2021 Results Report highlights the organization’s major achievements throughout the global health continuum. The report, which was published ahead of the World Health Assembly next week starting on May 23, highlights achievements such as the delivery of over 1.4 billion vaccine doses through the COVAX facility, the referral for widespread use of the world’s 1st malaria vaccine, and WHO’s response to 87 health crises, including COVID-19.

Partnering with 1600 technical and operational collaborators, WHO spearheaded the greatest-ever international response to a health crisis between 2020 and 2021, and helped catalyse the world’s largest, fastest, and most complicated inoculation effort. Necessary supplies for the COVID-19 reaction cost the organisation $1.7 billion.

Despite slashed funds and interrupted services, WHO Director-General Dr Tedros Adhanom Ghebreyesus said that even though WHO responded to the most serious global health crisis in a century, it actively supported the Member States in tackling many other risks to health. Even as the world reacts to and recovers from the pandemic throughout the coming years, WHO’s aim is to spend even more funds on their work in countries where it counts the most, he concluded. It is critical for WHO to have stable, consistent, and adaptable funding in order to execute its purpose of promoting health, keeping the world safe, and serving the defenseless.

By January 2022, the ACT-A alliance had distributed over 1 billion COVID-19 vaccination dosages. Nearly $500 million in personal protective equipment was sent globally, along with $187 million in oxygen supplies, $4.8 million in therapies, and 110 million diagnostic tests. However, much work has to be done in order for the world to meet WHO’s goal of inoculating 70% of its people by July 2022.

Beyond pandemic-WHO’s performance

Far beyond the pandemic, the results report demonstrates notable accomplishments. For 3.2 billion individuals in 58 countries, mandatory rules restricting the use of trans fatty acids (a dangerous dietary component linked to cardiovascular disease) have been put in place. Brazil, Peru, Singapore, Turkey, and the United Kingdom are among the 40 countries with best-practice policies. The WHO’s REPLACE effort intends to eliminate trans-fats from the world by the year 2023.

Tobacco usage is declining in 150 countries as a result of steps recommended by the WHO’s Framework Convention on Tobacco Control, saving lives and livelihoods. 15 countries have eliminated HIV and/or syphilis transmission from mother to child as a result of efforts to ramp up life-saving therapies guided by WHO guidelines. Over 1 million children have received the world’s first malaria vaccine (RTS, S), which was recommended by the WHO.

When combined with other malaria control interventions, it is anticipated to prevent 40,000 to 80,000 deaths each year.

An advocate for health equity

The report highlights WHO’s critical position as the world’s global health watchdog, advocating for equality in a planet marked by growing disparities. The pandemic’s devastating consequences were felt worldwide. The report depicts a world that is obviously falling behind on critical international health targets. Countries have fallen behind on WHO’s “Triple Billion objectives,” which provide crucial pathways to achieving the Sustainable Development Goals (SDGs) by 2030, owing to several interruptions created by the COVID-19. Universal health coverage and healthier populations are progressing at approximately a fourth of the rate required to meet the SDG’s by 2030, and no nation was totally prepared for a pandemic of this magnitude.

COVID-19 also caused massive disruptions in health services: 117 of 127 nations examined reported at least one vital health service disruption as a result of COVID, with an average disruption of 45%. The WHO’s ultimate purpose going forward will be to achieve the triple billion targets as a measurable way of closing health equity inequalities.

The relevance of long-term finance

The Results Report outlines WHO’s efforts to improve openness and accountability, as well as expenditure data. The WHO’s programme budget for 2020–2021 was $5,840.4 million. Due to COVID-19 emergency activities, financing totalled $7,916 million. The excess was made possible by the kindness of donors, notably 12 Member States, who gave over 71% of the overall budget. Nonetheless, donors direct the majority of WHO funding through defined voluntary contributions. In 2020-2021, flexible funds accounted for barely 20% of total funding.

The percentage of regular, stable, and predictable finance must increase if WHO is to play its full role in attaining the SDGs, delivering universal health coverage, lowering the burden of disease, and safeguarding 1 billion more individuals from health emergencies.

Previous Post

Proteros and AstraZeneca Boost Collaboration Agreement

Next Post

In Another Factory Expansion, Catalent Commits $175 Million

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Catalent Expands Nasal Drug Development and Manufacturing Capabilities at Morrisville, North Carolina, Facility

In Another Factory Expansion, Catalent Commits $175 Million

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In